{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092748","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.646888+00:00","generated_at":"2026-05-15T19:40:29.859356+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance","bullets":["Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.","Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.","New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.","Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.","Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092748","json":"https://secwatch.observer/filing/0001193125-26-092748.json","markdown":"https://secwatch.observer/filing/0001193125-26-092748.md","text":"https://secwatch.observer/filing/0001193125-26-092748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/0001193125-26-092748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:40:29.859356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}